Cipher Pharmaceuticals Inc Cash Flow Conversion Efficiency
Cipher Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has a cash flow conversion efficiency ratio of 0.022x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.98 Million ≈ $2.15 Million USD) by net assets (CA$137.03 Million ≈ $99.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cipher Pharmaceuticals Inc (2004–2025)
Cash flow conversion efficiency of Cipher Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Cipher Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cipher Pharmaceuticals Inc (CPH) stock price for real-time trading data and today's change.
Cipher Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Cipher Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cipher Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Cipher Pharmaceuticals Inc (CPH) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
-0.091x |
|
Icelandair Group hf
IC:ICEAIR
|
0.417x |
|
Provident Bancorp Inc
NASDAQ:PVBC
|
0.020x |
|
Perma-Pipe International Holdings Inc
NASDAQ:PPIH
|
0.065x |
|
National Aerospace Fasteners Corp
TW:3004
|
-0.010x |
|
Condor Energies Inc.
TO:CDR
|
0.082x |
|
Standard Biotools Inc
NASDAQ:LAB
|
-0.019x |
|
Global Partner Acquisition II Corp
NASDAQ:GPAC
|
0.297x |
Annual Cash Flow Conversion Efficiency for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cipher Pharmaceuticals Inc from 2004 to 2025. Review Cipher Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$126.01 Million ≈ $91.16 Million |
CA$30.25 Million ≈ $21.88 Million |
0.240x | +25.68% |
| 2024-12-31 | CA$102.34 Million ≈ $74.03 Million |
CA$19.55 Million ≈ $14.14 Million |
0.191x | -3.88% |
| 2023-12-31 | CA$80.52 Million ≈ $58.25 Million |
CA$16.00 Million ≈ $11.57 Million |
0.199x | +20.40% |
| 2022-12-31 | CA$64.08 Million ≈ $46.35 Million |
CA$10.57 Million ≈ $7.65 Million |
0.165x | -53.53% |
| 2021-12-31 | CA$38.90 Million ≈ $28.14 Million |
CA$13.81 Million ≈ $9.99 Million |
0.355x | -0.84% |
| 2020-12-31 | CA$32.64 Million ≈ $23.61 Million |
CA$11.69 Million ≈ $8.46 Million |
0.358x | +13.23% |
| 2019-12-31 | CA$28.01 Million ≈ $20.26 Million |
CA$8.86 Million ≈ $6.41 Million |
0.316x | -30.60% |
| 2018-12-31 | CA$24.76 Million ≈ $17.91 Million |
CA$11.28 Million ≈ $8.16 Million |
0.456x | -47.55% |
| 2017-12-31 | CA$22.94 Million ≈ $16.59 Million |
CA$19.93 Million ≈ $14.42 Million |
0.869x | +36.48% |
| 2016-12-31 | CA$18.01 Million ≈ $13.03 Million |
CA$11.47 Million ≈ $8.30 Million |
0.637x | +344.92% |
| 2015-12-31 | CA$54.26 Million ≈ $39.25 Million |
CA$7.76 Million ≈ $5.62 Million |
0.143x | +137.44% |
| 2014-12-31 | CA$6.62 Million ≈ $4.79 Million |
CA$-2.53 Million ≈ $-1.83 Million |
-0.382x | -298.20% |
| 2013-12-31 | CA$36.40 Million ≈ $26.33 Million |
CA$7.02 Million ≈ $5.08 Million |
0.193x | -65.14% |
| 2012-12-31 | CA$12.47 Million ≈ $9.02 Million |
CA$6.90 Million ≈ $4.99 Million |
0.553x | +744.04% |
| 2011-12-31 | CA$9.30 Million ≈ $6.73 Million |
CA$-799.22K ≈ $-578.14K |
-0.086x | -179.29% |
| 2010-12-31 | CA$11.47 Million ≈ $8.30 Million |
CA$1.24 Million ≈ $899.02K |
0.108x | +187.56% |
| 2009-12-31 | CA$10.47 Million ≈ $7.58 Million |
CA$-1.30 Million ≈ $-937.48K |
-0.124x | -50.64% |
| 2008-12-31 | CA$10.71 Million ≈ $7.74 Million |
CA$-879.21K ≈ $-636.01K |
-0.082x | +67.46% |
| 2007-12-31 | CA$15.83 Million ≈ $11.45 Million |
CA$-4.00 Million ≈ $-2.89 Million |
-0.252x | +58.75% |
| 2006-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$-11.27 Million ≈ $-8.15 Million |
-0.612x | +2.30% |
| 2005-12-31 | CA$19.16 Million ≈ $13.86 Million |
CA$-12.00 Million ≈ $-8.68 Million |
-0.626x | +2.30% |
| 2004-12-31 | CA$25.36 Million ≈ $18.34 Million |
CA$-16.26 Million ≈ $-11.76 Million |
-0.641x | -- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more